Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
M&A / Property

Kane Biotech signs with U.S. gov't distributor

By The Northwire Desk — AI Analysis Mar 10, 2026 · 17:40 KNE · 0.035 Kane Biotech Inc
KNE · Price

Executive Summary

  • Kane Biotech Inc. has entered into a strategic distribution partnership with Marathon Medical Corp., a federally verified service-disabled veteran-owned small business (SDVOSB), to expand its U.S. commercial footprint.
  • The partnership provides Kane Biotech with access to established U.S. government-authorized purchasing pathways, specifically targeting the Veterans Affairs (VA), Department of Defense (DOD), and Indian Health Services (IHS) markets for its revyve anti-microbial wound care portfolio.
  • Concurrently, the company is building a contract-based sales team with representatives across the U.S., with plans to continue expanding this group throughout 2026.

Key Details

  • Distribution Partner: Marathon Medical Corp., a leading nationwide medical supply distributor and SDVOSB.
  • Target Markets: U.S. Veterans Affairs (VA), U.S. Department of Defense (DOD), and U.S. Indian Health Services (IHS).
  • Product Portfolio: The partnership supports the commercialization of the revyve anti-microbial wound gel, revyve anti-microbial wound gel spray, and revyve anti-microbial skin and wound cleanser.
  • Regulatory Status: revyve products are U.S. FDA 510(k) cleared and Health Canada approved.
  • Sales Strategy: Kane Biotech is establishing a contract-based sales team with members located across the U.S.
  • Timeline: The sales team expansion is scheduled to continue throughout 2026.
  • Strategic Benefit: The partnership streamlines procurement, logistics, and product onboarding for the revyve wound care line within the federal health care supply chain.

Notable Quotes

  • "We are continuing to strategically build the commercial infrastructure required to make revyve a national brand in advanced wound care. Our new contract-based sales agents expand our reach into key markets, while our partnership with Marathon Medical, gives us a powerful foothold within the U.S. government system -- an essential step in making revyve accessible to the veterans, active service members and indigenous peoples." — Dr. Robert Huizinga, Interim Chief Executive Officer
Read the original news release →

More from Kane Biotech Inc

May 28, 2026 · 17:05

Liquidity Secured, Revenue Collapse Raises Execution Concerns

Earnings May 26, 2026 · 07:25

Kane Biotech Raises Capital Amidst Revenue Collapse; Dilution Concerns Persist

Financings May 07, 2026 · 07:25

Kane Biotech Seeks $1M Amidst Revenue Slump and Cash Burn Concerns

Financings Apr 23, 2026 · 18:00

Kane Biotech Revenue Plummets as Restructuring Costs Mount; Cash Runway Tightens

Earnings Apr 16, 2026 · 16:57

Clinical Validation Continues as Commercial Restart Struggles to Generate Revenue

Other Apr 16, 2026 · 07:25

Clinical Validation Supports Commercial Restart, But Revenue Collapse and Dilution Risks Remain

Other